Panacea Biotec Ltd
NSE: PANACEABIO BSE: 531349
₹347.55
(-1.75%)
Sun, 15 Mar 2026, 09:15 am
Market Cap21.73B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1984
- Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd.
1993
- The name of the Company changed to Panacea Biotec Limited
- Panacea Biotec proposed to expand the capacity of Vaccines Division, along with an expansion in the capacities of capsules and suspensions
1994
- Panacea Biotec used technology developed in-house and did not enter into any technical collaboration
1995
- Panacea Biotec made a public issue of 21,28,000 No. of Equity Shares of Rs. 10/- each for cash at a premium of Rs. 50/- per share
1996
- Panacea Biotec successfully commissioned a state-of-the-art Viral Vaccine Research facility at Latru near Chandigarh
1997
- Panacea Biotec introduced some speciality formulations like Nimulid
- Panacea Biotec filed applications for worldwide patents in 72 countries
2000
- Panacea Biotech explored opportunities for growth through expansion, diversification and backward integration
- Panacea Biotec proposed an amendment in articles of association for implementing the depository system for its stocks
- Panacea Biotec's product introductions like Nimulid, Livoluc, Nimulid gel, Risipid etc. were well received in the market
- Panacea Biotec entered into a joint venture with Heber Biotec Ltd (HBL) of Cuba to manufacture Hepatitis-B vaccine in bulk form
- Panacea Biotec set up another plant at Lalru to manufacture branded formulations for the export market
- Panacea Biotec planned to launch an anti-histamine drug
- Panacea Biotech set up two wholly-owned subsidiary companies in the UK and Hong Kong
- Panacea Biotec entered into an agreement with NSDL and CDSL for dematerialisation
2001
- Panacea Biotec signed an agreement with National Research Development Corporation (NRDC) to commercialise the know-how for an opthalmic formulation of ocular delivery, using nanotechnology
2002
- Panacea Biotec appointed Mr. Rajesh Jain and Mr. Sandeep Jain as the Joint Managing Directors of the company
- Panacea Biotec filed for a worldwide patent for its new NDDS for an anti-TB combination drug
- Panacea Biotec's Board approved the subdivision of shares from Rs.10 per share to Re.1 per share
- Panacea Biotec decided to wind up the company's wholly owned subsidiary at Isle of Man, UK
- A non-executive director made a gift of 2,01,000 shares of Re.1 each representing 0.35% of the company's total capital
- Panacea Biotec commenced marketing of herbal and dietary supplement products under its SBU viz. Best on Health
2003
- Panacea Biotec had a stock split from Rs 10 per equity share to Rs 1 per equity share
- Panacea Biotec forayed into the OTC market with Herbal Products
2004
- California-based Chiron Vaccines struck a deal with Delhi-based Panacea Biotec to set up a joint venture in India
- Panacea Biotec launched HEARTFELT, a natural therapy for cholesterol management developed by its Research and Development Team
- Panacea rolls out new nimesulide injection
- Panacea Biotec launched Combination vaccines through a JV with Chiron Vaccines, UK
2005
- Panacea Biotec launched Upright for effective relief from severe pain and inflammation
- Panacea Biotec introduced Noval Anti-allergy Drug - Ralif
2006
- Panacea Biotec entered into an agreement with PT Bio Farma to manufacture Measles Vaccine
2007
- Panacea Biotec signed an agreement with Family Vaccines to supply combination vaccines
2009
- Panacea Biotec received a USD 222.37 million Award from UNICEF for EasyFive Injects
2010
- Panacea Biotech's Baddi unit received US FDA approval
- Panacea Bio's Board recommended a dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10
2011
- Panacea Biotec launched PacliALL
- Panacea Biotec announced plans to foray into the healthcare infrastructure sector with the setting up of a multi-specialty hospital in Gurgaon, Haryana
2012
- Panacea Biotec celebrated the 63rd Indian Republic day with the launch of POLPROTEC in Nigeria
- Panacea Biotech launched Inactivated Polio Virus vaccine in Nigeria
- Panacea Biotec inaugurated a state-of-the-art Oncology Production Unit
- Panacea Biotec entered into a strategic alliance with Osmotica Pharmaceutical
- Panacea Biotec won an order worth Rs 187 cr from the Government to supply polio vaccines
2013
- Panacea Biotec opened its wholly owned subsidiary in UAE in the name of Panol Industries
2014
- Panacea Biotec entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA
- Panacea Biotec announced collaboration with Rising Pharmaceuticals Inc.
- Panacea Biotec received a UNICEF Award for supply of the Company's DTB-HebB-Hib (Pentavalent) Vaccine Easyfive-TT to UNICEF
2015
- Panacea Biotec received an order from the Pan American Health Organization (PAHO) for supply of EasyFive-TT Vaccines worth
2016
- Panacea Biotec launched CABAPAN, a cost-effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)
- Panacea Biotec received the prestigious Intellectual Property and Science Award Top 50 Indian Innovators 2015
- Panacea Biotec launched TENEPAN, a cost-effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)
- Panacea Biotec introduced the World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib
2017
- Panacea Biotec introduced the World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases
- Panacea Biotec announced ANDA approval for US Market and LTA and Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT)
- Panacea Biotec announced a joint collaboration with Bionpharma Inc.
2018
- Panacea Biotec inked a Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market
2019
- Panacea Biotec launched ViLACT for treatment of uncontrolled Type 2 Diabetes Mellitus patients
- Panacea Biotec received a USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies
2021
- RDIF and Panacea Biotec launched the production of Sputnik V in India
- Panacea Biotec supplied the first shipment of the second component of Sputnik V vaccine produced in India
2022
- Panacea Biotec received UNICEF and PAHO awards for supply of Pentavalent Vaccine
- CEPI, THSTI and Panacea Biotec partnered to develop broadly protective Betacoronavirus vaccines
2023
- Panacea Biotec launched EasyFourPol in India
- Panacea Biotec received registration of Valganciclovir Powder for Oral Solution in Germany
- Panacea Biotec launched Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane
- Panacea Biotec's wholly owned subsidiary launched a new range of high-quality pediatric food and nutritional products in India
2024
- The Company received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth US$ 14.95 million.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800